
News|Poll|March 27, 2015
Have You Heard This (Week's) News?
Author(s)Susan Kweskin
Advertisement
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema. The FDA previously approved ranibizumab (Lucentis, Roche) for the same indication.
Eylea (aflibercept) injection is also indicated for treatment of which of the following?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Investigational Dual GLP-1/GIP Agonist CT-388 Demonstrates 22.5% Placebo-Adjusted Weight Loss in Phase 2 Obesity Trial
2
Colorectal Cancer Becomes Leading Cause of Cancer Death in US Adults Younger Than 50 Years, Study Finds
3
Centanafadine Granted FDA Priority Review for the Treatment of ADHD Across Pediatric and Adult Populations
4






























































































































